## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)		
YAN et al.	)		
Serial No.: Unassigned	)	Group Art Unit: Unassigned	
Filed: November 29, 2001	)	Examiner:	Unassigned
For: COMPOUNDS AND METHODS FOR THE MODULATION OF CD154	) ) )		

## **COMPLIANCE UNDER 37 C.F.R. §§1.821-1.825**

Assistant Commissioner of Patents

Washington, D.C. 20231

Sir:

In compliance with the Requirements for Patent Applications containing Nucleotide Sequences and/or Amino Acid disclosures, Applicants submit the following for the above-identified application:

- a) An initial computer readable form copy of the "Sequence Listing"; and
- b) An initial paper copy of the "Sequence Listing."

The content of the paper and the computer readable copy are the same and, where applicable include no new matter, as required by 37 C.F.R. §1.821(e)-1.821(g) or 1.825(b) or 1.825(d).

In re Application of Yan et U.S. Application Serial No.



In view of the above remarks, Applicants submit that they have complied with the requirements under 37 C.F.R. §1.821-1.825. It is submitted that the claims are now in condition for examination. In the event that there are any problems which can be expedited by telephone conference, the Examiner is invited to telephone the undersigned at the number indicated below.

Respectfully submitted,

Rν·

Carmen Pili Ekstrom Reg. No. 34,981

COR Therapeutics, inc. 256 E. Grand Ave. South San Francisco, CA 94080 (650) 244-6896 Dated: 11/29/2001 Atty. Dkt. No.: COR 148

Enclosures: (A) Computer disk of sequence listing

(B) Paper copy of sequence listing